Janošťáková Anna M.Sc.

Janošťáková Anna M.Sc.'s picture
Phone: +420 585 632 128, +420 585 632 145

Publications (Impact Factor Journals):

  • [5]
    ČÍŽKOVÁ, M., K. BOUCHALOVÁ, D. FRIEDECKÝ, A. POLYNKOVA, A. JANOŠŤÁKOVÁ, L. RADOVÁ, K. CWIERTKA, R. TROJANEC, M. ZEZULOVÁ, M. ZLEVOROVA, M. HAJDÚCH a B. MELICHAR. High lapatinib plasma levels in breast cancer patients: risk or benefit?. Tumori. 2012, 98(1), 162-165. ISSN 0300-8916. IF: 0.922. PMID: 22495718
  • [4]
    KOPŘIVA, F., A. JANOŠŤÁKOVÁ, J. SZOTKOWSKA, M. ZAPALKA a M. HAJDÚCH. Montelukast decreases plasma endothelin-1 and serum eosinophil cationic protein levels in paediatric atopic asthma. Clinical Drug Investigation. 2006, 26(6), 351-356. ISSN 1173-2563. IF: 0.707. PMID: 17163269
  • [3]
    ŠAREK, J., P. DŽUBÁK, E. KLINOTOVÁ, V. NOSKOVA, V. KŘEČEK, G. KOŘÍNKOVÁ, J.O. THOMSON, A. JANOŠŤÁKOVÁ, S. WANG, S. PARSONS, P.M. FISCHER, N. ZHELEV a M. HAJDÚCH. New lupane derived compounds with Pro-Apoptotic activity in cancer cells: Synthesis and structure-activity relationships. Journal of Medicinal Chemistry. 2003, 46(25), 5402-5415. ISSN 0022-2623. IF: 4.566. PMID: 14640549
  • [2]
    NOSKOVA, V., P. DŽUBÁK, G. KUZMINA, A. LUDKOVÁ, D. STEHLÍK, R. TROJANEC, A. JANOŠŤÁKOVÁ, G. KOŘÍNKOVÁ, V. MIHÁL a M. HAJDÚCH. In vitro chemoresistance profile and expression/function of MDR associated proteins in resistant cell lines derived from CCRF-CEM, K562, A549 and MDA MB 231 parental cells. Neoplasma. 2002, 49(6), 418-425. ISSN 0028-2685. IF: 0.637. PMID: 12584592
  • [1]
    MIHÁL, V., M. HAJDÚCH, V. NOSKOVA, A. JANOŠŤÁKOVÁ, M. SAFAROVA, M. OREL, G. KUZMINA, B.. BLAZEK a D. POSPÍŠILOVÁ. The analysis od correlations between drug resistance and clinical/laboratory measures found in a group of children with all treated by ALL-BFM 90 protocol. Bulletin du Cancer. 2004, 91(4), -. ISSN 0007-4551. IF: 0.654.